Board Review

Date: 
Thursday, August 27, 2020 - 8:00am to 9:00am
Short description: 
Discussion of basic science and phase 3 clinical trial data for Aducanumab, a monoclonal antibody currently in front of the FDA. This drug binds aggregated forms of parenchymal Aβ and the anticipated indication is dementia with a potential approval date in 3-6 months.
Location: 
10 West Conference Room, Sparrow Hospital / Join Zoom Meeting https://msuhipaa.zoom.us/j/95115878830?pwd=MDdRZlNWbUJqOXdiaTZOeGtROURvQT09 Password: 287271
Topic / Activity: 
Board Review
Speakers / Presenters: 
Dr. Karen Running, Biogen
Conferences: 
Board Review Schedule
Dr Karen Running is a Senior Medical Scientist from Biogen. She will be discussing basic science and phase 3 clinical trial data for Aducanumab, a monoclonal antibody currently in front of the FDA. This drug binds aggregated forms of parenchymal Aβ and the anticipated indication is dementia with a potential approval date in 3-6 months.
 

Developed by DECS | Contact Information | Privacy Statement | Site Accessibility

© Michigan State University Board of Trustees, East Lansing, MI 48824